Market News & Trends
RedHill Biopharma Provides Update on Ongoing Phase II & III Studies
RedHill Biopharma Ltd. recently provided an update on its ongoing Phase III and Phase II clinical studies with BEKINDA for the treatment of acute gastroenteritis…
Mylan & BioCon Announce Regulatory Submission
Mylan N.V. and Biocon Ltd. recently announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for insulin glargine,…
FDA Accepts Genentech’s Biologics License Application
Halozyme Therapeutics, Inc. recently announced that the US FDA has accepted Genentech's Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer…
Evonik Industries Submits Bid for Technology Platform
Amino acids produced by fermentation are an important pillar of Evonik’s product portfolio for sustainable animal nutrition. The production processes for Biolys (lysine), ThreAMINO (threonine),…
Caris Life Sciences Designates West Virginia University Cancer Institute a Center of Excellence
Caris Life Sciences recently announced the designation of the West Virginia University (WVU) Cancer Institute as a center of excellence site in the Caris Centers…
Progenics Announces $50-Million Infusion to Advance Portfolio
Progenics Pharmaceuticals, Inc. recently announced its wholly owned subsidiary MNTX Royalties Sub LLC has entered into a $50-million term loan agreement with a fund managed…
Positive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder Space
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according…
Avacta Announces CAR-T Cell Therapy Research Collaboration
Avacta Group plc recently announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in novel…
Kamada Announces Plan for Phase II/III Clinical Trial
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States of its Alpha-1 Antitrypsin (G1-AAT…
Atara Bio to Present Results From Phase II Trial
Atara Biotherapeutics, Inc. recently announced Phase II results from its allogeneic T-cell product candidate, CMV-CTL, will be presented by its collaborating investigators at Memorial Sloan…
MorphoSys & LEO Pharma Enter Strategic Alliance
MorphoSys AG and LEO Pharma recently announced they have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
BioSun & ARTES Announce Co-Development Agreement for HPV Vaccine
BioSun Pharmed and ARTES Biotechnology recently announced they will join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran.…
Aclaris Therapeutics Submits IND Application for ATI-50001
Aclaris Therapeutics, Inc. recently announced that it has submitted an Investigational New Drug Application (IND) to the US FDA for its drug candidate ATI-50001 for…
Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion,…
Daiichi Sankyo & Inspirion Delivery Sciences Announce Licensing Agreement
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC recently announced the companies have entered into a strategic collaboration agreement in the US to commercialize FDA-approved…
BIOPHYTIS Chooses Patheon to Produce Clinical Batches
BIOPHYTIS recently announced it has entered into an agreement with US firm Patheon for the industrial scale-up and manufacturing of clinical batches, the first stage…
Selecta Biosciences Initiates Phase II Clinical Trial
Selecta Biosciences, Inc. recently announced it has dosed the first patient in its Phase II clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product…
Proteon Therapeutics Announces Overview of Phase I Clinical Program
Proteon Therapeutics, Inc. recently announced that an overview of the company’s Phase I clinical program of investigational vonapanitase in peripheral artery disease (PAD) was presented…
Pluristem Signs Term Sheet for $30-Million Equity Investment Agreement
Pluristem Therapeutics Inc. recently announced it has signed a term sheet for an investment of approximately $30 million by China-based Innovative Medical Management Co., Ltd.,…
Parion Sciences Announces Presentation of Clinical Data With Novel Pulmonary Delivery Device
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, recently announced that an abstract from its pulmonary research…
